A Phase IB Dose Escalation Study of Lipocurc in Patients With Cancer
Status:
Unknown status
Trial end date:
2017-06-30
Target enrollment:
Participant gender:
Summary
This is a single center in patient/outpatient, uncontrolled dose escalating study in cancer
patients to evaluate the safety, tolerability and pharmacokinetic (PK) profiles of body
surface area adjusted doses of liposomal curcumin administered intravenously as an 8 hour
infusion once weekly for 8 weeks.